Osmind

Osmind provides a specialized platform for clinicians and researchers focused on advancing new mental health treatments. Addressing the critical issue of mental health disorders, which are among the leading causes of death globally, Osmind offers a unique solution for neuropsychiatric clinics. The platform supports both general and interventional psychiatry, including treatments like transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, and electroconvulsive therapy. Its core electronic health record (EHR) technology is tailored to interventional treatment workflows and enhances the therapeutic alliance with features such as journaling tools and assistance with health plan reimbursement. Research conducted using Osmind's platform contributes to setting new standards for mental health interventions. Notably, a collaboration with Stanford University School of Medicine led to the publication of the largest real-world analysis of ketamine infusion therapy for depression in the Journal of Affective Disorders (March 2022). Ongoing research studies utilize proprietary real-world data and machine learning to predict treatment outcomes, further advancing the field of mental health.